In late 2024, the Centers for Medicare and Medicaid Services previewed a significant revision to the risk-adjustment model ...
With a Senate vote looming and reports of an impending White House proposal, this article discusses what has transpired in ...
Health Affairs' Rob Lott interviews Tiffany Lemon of Arizona State University on her recent paper exploring the concept of ...
In this piece, we explore reasons for creating a separate conversion factor within the MPFS, initially for advanced primary ...
As policy makers pursue price transparency, they should consider what additional measures could serve as a complement to ...
With collaboration and evidence-based approaches, we can build a patient-centric health care system that works better for ...
The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...
The real gold standard for science, and academic freedom, requires upholding scientific work that investigates who and what ...
We aim to provide transparency in how Elevance Health plans address variations in clinical practices to ensure safe, ...
The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...
The No UPCODE Act—with some refinements—is a good start insofar it establishes some key pieces of reform, but a broader ...
When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback